BERLIN and SEATTLE, March 30, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported its financial results for the fiscal year ending December 31, 2006, and presented its strategy realignment aiming at the fastest route to commercialization.
